Myriad Genetics (MYGN) Change in Acquisitions & Divestments (2009 - 2024)

Myriad Genetics (MYGN) has 16 years of Change in Acquisitions & Divestments data on file, last reported at $5.0 million in Q3 2024.

• Change in Acquisitions & Divestments for Q3 2024 came in at $5.0 million, down 66.67% year-over-year; the trailing twelve-month figure through Jun 2025 was $5.0 million (down 75.61% YoY), and the FY2024 annual result was $9.0 million, down 91.44% from the prior year.
• Change in Acquisitions & Divestments grew to $5.0 million in Q3 2024 per MYGN's latest filing, from $2.5 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $58.1 million in Q1 2023 and troughed at $1.5 million in Q4 2023.
• A 5-year average of $21.7 million and a median of $18.6 million in 2020 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2020 and 2024: Change in Acquisitions & Divestments soared 318.9% in 2020, then sank 97.42% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $35.9 million in 2020, then sank by 32.31% to $24.3 million in 2021, then surged by 67.08% to $40.6 million in 2022, then tumbled by 96.31% to $1.5 million in 2023, then surged by 233.33% to $5.0 million in 2024.
• Business Quant data shows MYGN's Change in Acquisitions & Divestments at $5.0 million in Q3 2024, $2.5 million in Q2 2024, and $1.5 million in Q1 2024.